| Methods |
Allocation: randomised ‐ no further details.
Blindness: not reported.
Duration: 12 weeks. |
| Participants |
Diagnosis: schizophrenia (CCMD‐2‐R).
N=105.
Sex: male and female.
Age: average 29 years.
History: length of illness three months to three years. |
| Interventions |
1. Clozapine: dose 25 to 600 mg/d. N=35.
2. Chlorpromazine: dose 25 to 600 mg/d. N=35.
3. Risperidone: dose 1 to 7 mg/d. N=35. |
| Outcomes |
Mental state: PANSS.
Adverse events: TESS |
| Notes |
outcome: PANSS endpoint score, change score, curative effect, adverse events. CSG: 10006 |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Adequate sequence generation? |
Unclear risk |
Randomised ‐ no details |
| Allocation concealment? |
Unclear risk |
No details |
| Blinding?
All outcomes |
Unclear risk |
Not reported |
| Incomplete outcome data addressed?
All outcomes |
High risk |
Study attrition not reported |
| Free of selective reporting? |
Unclear risk |
No details |
| Free of other bias? |
Unclear risk |
Unclear |
